Compare Amgen, Inc. (AMGN) vs Kingsoft Cloud Holdings Limited (KC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Kingsoft Cloud Holdings Limited — how do they compare? Amgen, Inc. trades at $415.01 (market cap $224.14B), while Kingsoft Cloud Holdings Limited trades at $11.64 (market cap $3.53B). The key difference: Amgen, Inc. is far larger — about 63.5× Kingsoft Cloud Holdings Limited's market cap, and Amgen, Inc. pays a 2.43% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals.
| AMGN | KC | |
|---|---|---|
Market Cap | $224.14B | $3.53B |
Sector | Health | Technology |
52-Week High | $417.20 | $18.21 |
52-Week Low | $271.18 | $8.58 |
Enterprise Value | $267.45B | $3.84B |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Kingsoft Cloud (KC) trades at $11.66, down 2.55% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue growth of 37% year-over-year in Q1 2026, driven by AI cloud services, but net income remains negative at -$936 million for 2025. Analyst consensus is strongly bullish with 70% buy ratings, citing AI-driven expansion and undervaluation relative to peers.
The outlook is positive due to AI revenue acceleration and analyst optimism, but risks include persistent losses, high capital expenditure, and competitive pressures in China's cloud market. Investors should weigh growth potential against profitability challenges ahead of Q2 2026 earnings on August 19, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Kingsoft Cloud Holdings Limited
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →
